Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | -£0 | -£0 | -£1 | -£0 |
| % Margin | – | – | – | – |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £2 | £2 | £0 | £2 |
| SG&A Expenses | £2 | £2 | £2 | £2 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£0 | £0 | -£0 |
| Operating Expenses | £2 | £2 | £2 | £2 |
| Operating Income | -£3 | -£3 | -£0 | -£2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -£2 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£5 | -£3 | -£0 | -£2 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£5 | -£3 | -£0 | -£2 |
| % Margin | – | – | – | – |
| EPS | -1.42 | -0.8 | -0.001 | -0.81 |
| % Growth | -77.5% | -88,788.9% | 99.9% | – |
| EPS Diluted | -1.42 | -0.8 | -0.001 | -0.81 |
| Weighted Avg Shares Out | 4 | 4 | 3 | 3 |
| Weighted Avg Shares Out Dil | 4 | 4 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £1 | £0 |
| EBITDA | -£5 | -£2 | -£5 | -£2 |
| % Margin | – | – | – | – |